News und Analysen
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2022 financial results on Wednesday, August 3rd, before the market opens. A conference call has been scheduled
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Nanobiotix (Paris:NANO)(NASDAQ:NBTX)
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: w
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter of 2022.
Press release date / time: Wednesday, July 27, shortly after 22:05
Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA
Regulatory News:
Lysogene (Paris:LYS)(FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today communicates additional preliminary data
Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
AMN Healthcare to Hold Second Quarter 2022 Earnings Conference Call on Thursday, August 4, 2022
AMN Healthcare Services, Inc. (NYSE: AMN) has scheduled a conference call to discuss its second quarter 2022 financial results and third quarter 2022 outlook on Thursday, August 4, 2022, at 5:00
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its third
Chemed To Report Second-Quarter 2022 Earnings July 27, Related Conference Call To Be Held On July 28
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2022, on Wednesday, July 27, 2022, following the close of trading on the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022
Teva Uses the Agilent TRS100 to Achieve Regulatory Milestone for Content Uniformity Testing with the FDA
Agilent Technologies Inc. (NYSE: A) announced today that the FDA has approved a content uniformity (CU) method using the Agilent TRS100 Raman quantitative pharmaceutical analysis system.
The
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Pharnext Appoints Antoine Gravelle as General Counsel